Various other therapeutic C5 inhibitors (crovalimab, LFG316, REGN3918, ABP959, elizaria, and zilucoplan) are under ongoing clinical investigation for PNH treatment [8,9,10,11,12]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.